CAPTRUST Financial Advisors
TVTX icon

CAPTRUST Financial Advisors’s Travere Therapeutics TVTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Buy
28,636
+6,698
+31% +$297K ﹤0.01% 1440
2026
Q1 		$652K Buy
21,938
+1,235
+6% +$36.9K ﹤0.01% 1859
2025
Q4 		$791K Buy
20,703
+1,767
+9% +$57.5K ﹤0.01% 1635
2025
Q3 		$453K Buy
+18,936
New +$356K ﹤0.01% 1885
2024
Q1 		– Sell
-24,980
Closed -$225K – 2641
2023
Q4 		$225K Sell
24,980
-15,205
-38% -$111K ﹤0.01% 2308
2023
Q3 		$359K Buy
40,185
+14,163
+54% +$200K ﹤0.01% 1876
2023
Q2 		$400K Buy
+26,022
New +$473K ﹤0.01% 1765
2022
Q3 		– Sell
-168
Closed -$4K – 3917
2022
Q2 		$4K Hold
168
– – ﹤0.01% 4220
2022
Q1 		$4K Hold
168
– – ﹤0.01% 4283
2021
Q4 		$5K Hold
168
– – ﹤0.01% 4096
2021
Q3 		$4K Buy
+168
New +$3.09K ﹤0.01% 4058

Other funds holding TVTX

JTL
Jupiter Topco LLC New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CAPTRUST Financial Advisors's TVTX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Travere Therapeutics (TVTX) stake by 31% in Q2 2026, buying an estimated $297K and bringing the position to 28,636 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1440.

CAPTRUST Financial Advisors first reported a position in TVTX in Q3 2021 and has held it in 11 quarters since. 289 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • CAPTRUST Financial Advisors held 28,636 shares of Travere Therapeutics worth $1.63M as of Q2 2026.
  • CAPTRUST Financial Advisors bought 6,698 Travere Therapeutics shares in Q2 2026, an estimated $297K.
  • Travere Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1440 holding.
  • CAPTRUST Financial Advisors first reported a position in Travere Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • 289 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.